{
    "Case ID": "063405",
    "Crime_Name": [
        "Patent Eligibility Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Eligibility Dispute"
    ],
    "Legal_Issue": [
        "Is the '753 Patent eligible for inclusion on the Patent Register under the Regulations?"
    ],
    "Governing_Law": [
        "par. 4(2)(b) of the Regulations"
    ],
    "Procedural_Stage": [
        "Motion brought under par. 6(5)(a)"
    ],
    "Evidence_Assessment": [
        "evidence reviewed, claims analyzed, and legal precedents considered"
    ],
    "Decision_Outcome": [
        "Application dismissed"
    ],
    "Burden_of_Proof": [],
    "Credibility_Factor": [],
    "Legal_Rule": [
        "Under par. 4(2)(b) of the Regulations, a patent must contain a claim for the medicine itself or its use to be eligible for inclusion."
    ],
    "Standard_of_Review": [],
    "Procedural_Issue": [
        "Motion under par. 6(5)(a)"
    ],
    "Grounds_for_Claim": [
        "The '753 Patent primarily describes a delivery system applicable to numerous active ingredients, including lansoprazole; claims related to lansoprazole are narrow expressions of the delivery system, not claims to the medicine or its use."
    ],
    "Outcome_on_Merits": [
        "The '753 Patent is not eligible for inclusion on the Register"
    ],
    "Decision_Maker": [],
    "Judicial_Review_Outcome": [
        "Application dismissed"
    ],
    "Review_Standard": [],
    "Procedural_Fairness_Assessment": [],
    "Key_Evidence_Considered": [
        "Claims of the '753 Patent",
        "Description of the delivery system",
        "Applicability to lansoprazole"
    ],
    "Legal_Framework": [
        "Regulations governing patent listing on the Patent Register"
    ],
    "Applicant_Challenge": [
        "Novopharm sought dismissal of Abbott's prohibition application"
    ],
    "Court_Result": [
        "Application dismissed; Novopharm awarded costs; Takeda also awarded costs"
    ],
    "Legal_Rule_Source": [
        "par. 4(2)(b) of the Regulations"
    ],
    "Standard_of_Proof": [],
    "Defendant_Response": [
        "Novopharm challenged eligibility of the '753 Patent"
    ],
    "Evidence_Type": [
        "Patent claims",
        "Legal precedents",
        "Technical description"
    ],
    "Remedy_Requested": [
        "Dismissal of prohibition application"
    ],
    "Outcome": [
        "Dismissed under par. 6(5)(a)"
    ],
    "Decision_Authority": [],
    "Remedy_Sought": [
        "Costs awarded to Novopharm and Takeda"
    ],
    "Resolution_Mechanism": [
        "Motion under regulatory provisions"
    ],
    "Legal_Provision": [
        "par. 4(2)(b)",
        "par. 6(5)(a)"
    ],
    "Authority": [],
    "Claimant_Status": [],
    "Legal_Provision_Cited": [
        "par. 4(2)(b)",
        "par. 6(5)(a)"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Patent does not claim the medicine or its use"
    ],
    "Applicable_Process": [
        "Regulatory patent listing process"
    ],
    "Outcome_of_Review": [
        "Application dismissed"
    ],
    "Pending_Relief_or_Application": [
        "Prohibition application"
    ],
    "Jurisdiction": [],
    "Governing_Rule": [
        "par. 4(2)(b) of the Regulations"
    ]
}